Ultrasound-targeted antisense oligonucleotide attenuates ischemia/reperfusion-induced myocardial tumor necrosis factor-alpha

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 1, 2003, Pages 119-130

  Erikson, John M ^a   Freeman, Gregory L ^b   Chandrasekar, Bysani ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Antisense oligonucleotides; Contrast; Ischemia reperfusion injury; Ultrasound

Indexed keywords

ALBUMIN; ANTISENSE OLIGONUCLEOTIDE; FLUOROCARBON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATTENUATION; CYTOKINE PRODUCTION; DRUG TARGETING; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; INOTROPISM; MEDIATOR RELEASE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; RAT STRAIN; REPERFUSION INJURY; SUPERIOR CAVA VEIN; ULTRASOUND; WESTERN BLOTTING;

MYOCARDIUM; OLIGONUCLEOTIDES, ANTISENSE; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONICS;

ANIMALIA;

EID: 0037215799     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(02)00289-4     Document Type: Article

References (32)

1. Srinivasan S.K., Tewary H.K., Iversen P.L. Characterization of binding sites, extent of binding, and drug interaction of oligonucleotides with albumin. Antisense. Res Dev. 5:1995;131-139.
2. Porter T.R., Iversen P.L., Li S., Xie F. Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J Ultrasound M. 15:1996;577-584.
3. Wong J., Mukherjee D., Porter T., Young D., Sen S., Thomas J. Ultrasound enhances PESDA linked oligonucleotide deposition into myocardial tissue [abstract]. J Am Soc Echo. 11:1998;498 RC.
4. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol. 274:(Regulatory Integrative Comp Physiol 43):1998;R577-R595.
5. Chandrasekar B., Colston J.T., Freeman G.L. Induction of proinflammatory cytokine and antioxidant enzyme gene expression following brief myocardial ischemia. Clin Exp Immunol. 108:1997;346-351.
6. Maury C.P.J., Teppo A- M. Circulating tumor necrosis factor-α (cachexin) in myocardial infarction. J Int M. 225:1989;333-336.
7. Başaran Y., Başaran M.M., Babacan K.F., et al. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology. 44:1993;332-337.
8. Latini R., Bianchi M., Correale E., et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharm. 23:1994;1-6.
9. Hirschl M.M., Gwechenberger M., Binder T., et al. Assessment of myocardial injury by serum tumor necrosis factor alpha measurements in acute myocardial infarction. Eur Heart J. 17:1996;1852-1859.
10. Pagani F.D., Baker L.S., Hsi C., Knox M., Fink M.P., Visner M.S. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 90:1992;389-398.
11. Suffredini A.F., Fromm R.E., Parker M.M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J M. 321:1989;280-287.
12. Murray D.R., Freeman G.L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res. 78:1995;154-160.
13. Odeh M. Tumor necrosis factor-a as a myocardial depressant substance. Int J Card. 42:1993;231-238.
14. Chandrasekar B., Mitchell D.H., Colston J.T., Freeman G.L. Regulation of CCAAT/enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation. 99:1999;427-433.
15. Ioculano M., Altavilla D., Squadrito F., et al. Tumor necrosis factor mediates E-selectin production and leukocyte accumulation in myocardial ischaemia-reperfusion injury. Pharmacol Res. 31:1995;281-288.
16. Warner S.J.C., Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 142:1989;100-109.
17. Porter T.R., Kricsfeld A., Deligonul U., Xie F. Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin. Am Heart J. 132:1996;41-47.
18. Porter T.R., Xie F., Kricsfeld D., Armbruster R.W. Improved myocardial contrast with second harmonic transient ultrasound response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextrose albumin. J Am Coll Card. 27:1996;1497-1501.
19. d'Hellencourt C.L., Diaw L., Cornillet P., Guenounou M. Inhibition of human TNF-a and LT in cell-free extracts and in cell culture by antisense nucleotides. Biochim et Biophys Acta. 1317:1996;168-174.
20. Eckstein F. Nucleoside phosphorothioates. Ann Rev Biochem. 54:1985;367-402.
21. Shohet R.V., Chen S., Zhou Y- T., et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation. 101:2000;2554-2556.
22. Mukherjee D., Wong J., Griffin B., et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol. 35:2000;1678-1686.
23. Li P., McCreery T., Mathew B., et al. In vivo transfection and gene expression in canine myocardioum after intravenous injection of microbubble-linked plasmid DNA and exposure to ultrasound [abstract]. J Am Soc Echo. 13:2000;481 402V.
24. Wei K., Skyba D.M., Firschke C., Jayaweera A.R., Lindner J.R., Kaul S. Interactions between microbubbles and ultrasound: in vitro and in vivo observations. J Am Coll Cardiol. 29:1997;1081-1088.
25. Skyba D.M., Price R.J., Linka A.Z., Skalak T.C., Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation. 98:1998;290-293.
26. Price R.J., Skyba D.M., Kaul S., Skalak T.C. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation. 98:1998;1264-1267.
27. Cain B.S., Meldrum D.R., Dinarello C.A., Meng X., Joo K.S., Banerjee A., et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care M. 27:1999;1309-1318.
28. Ikeda U., Ohkawa F., Seino Y., Yamamoto K., Hidaka Y., Kasahara T., et al. Serum interleukin 6 levels elevated in acute myocardial infarction. J Mol Cell Cardiol. 24:1992;570-584.
29. Miyao Y., Yasue H., Ogawa H., Misumi I., Masuda T., Sakamoto T., et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 126:1993;1299-1304.
30. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 101:(15):1998;311-320.
31. Bolli R. Myocardial "stunning" in man. Circulation. 86:1992;1671-1691.
32. Bolli R., Hartley C.J., Rabinovitz R.S. Clinical relevance of myocardial "stunning" Cardiovasc Drugs Ther. (5):1991;877-890.